Investigators at the Stephenson Cancer Center at OU Medicine recently gave 30 presentations about their cancer research at an annual ASCO Chicago meetings. The OU Medicine presentations focused on the results of clinical trials and research studies for new cancer therapies being developed and evaluated at the Stephenson Cancer Center.
Sooner State Record-Setting Number of Presentations
Oklahoma investigators from the Stephenson Cancer Center showed up in the largest numbers due to the dynamic and breakthrough activities of “Sooner State” scientists—30 abstracts selected from one center is impressive.
What follows is a summary of some of the activity of the Stephens Center:
- A large study that establishes the standard of care in uterine carcinosarcoma (a rare and aggressive type of uterus cancer)
- A study that adds a novel oral therapy called PARP inhibitor to chemotherapy for ovarian cancer
- Addition of immunotherapy to radiation and chemotherapy for head and neck cancers
Results involved several types of cancer including ovarian, uterine, cervical, urothelial, head and neck, pancreatic, lung, leukemia, pediatric leukemia, skin, and pediatric sarcoma.
Several presentations focused on the results of early phase clinical trials being conducted at the Oklahoma TSET Phase I Program. Early phase trials provide patients with first access to the newest targeted therapies for cancer. The TSET Phase I Program at the Stephenson Cancer Center is ranked among the top 10 nationally for the number of patients participating in research trials.
Kathleen Moore, MD, associate director for clinical research at the Stephenson Cancer Center noted “I am incredibly product of the research being done at the Stephenson Cancer Center. We have an amazing team of clinician and translational scientists who work together internally and collaborate externally within the National Cancer Institute, pharmaceutical companies, and other NCI cancer centers to drive research forward and advance therapies.”
About the Stephenson Cancer Center
It has earned National Cancer Institute designation in May 2018. NCI centers represent the top 2 percent of cancer centers in the United States. The Stephenson is the only NCI-designated Cancer Center in Oklahoma. The University of Oklahoma Health Sciences Center is the state’s only comprehensive academic health system of hospitals, clinics, and centers of excellence. It represents the largest and most comprehensive oncology practice in the state, delivering patient-centered, multidisciplinary care for every type of cancer.
With 11,000 employees and more than 1,300 physicians and advanced practice providers, OU Medicine is home to Oklahoma’s largest physician network with a complete range of specialty care. OU Medicine services Oklahoma and the region with the state’s only freestanding children’s hospital, the only National Cancer Institute-designated Stephenson Cancer Center and Oklahoma’s flagship hospital which serves as the state’s only Level 1 trauma center.